Apixaban Reduces Risk of Recurrent Venous Thromboembolism

Apixaban Reduces Risk Of Recurrent Venous Thromboembolism

Filed under: drug treatment news 2012

The drug is currently used in Europe, but not in the U.S where it is still awaiting approval. The main treatment for venous thromboembolism is Warfarin. More research is necessary to compare the effectiveness of Apixaban to this drug; this is expected …
Read more on Medical News Today

Research identifies targeted molecular therapy for untreatable NF1 tumors

Filed under: drug treatment news 2012

Researchers then tested different doses of the drug to identify an optimal dose – one that would achieve the maximum amount of tumor shrinking efficiency with the least amount of toxicity. Treatment with PD0325901 reduced the abnormal growth of cells …
Read more on Medical Xpress

The Cancer Bomb: How Nuclear Sludge Gave Birth to an Experimental …

Filed under: drug treatment news 2012

The ability to target the cancer-killing agent with high precision was a breakthrough, but the short half-life meant that the treatment could only be administered near the laboratory where the drug was created, making it unfeasible for widespread …
Read more on New York Observer